|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin.
|
30988680 |
2019 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
|
27735085 |
2017 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.
|
28703131 |
2017 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
This study assessed frequency of the IL-28 polymorphism (rs8099917) in 50 patients (39 men and 11 women ) with chronic hepatitis C using ZNA probe real time PCR new method .
|
25773845 |
2015 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
The three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA genotype of rs12980275) were associated with the SVR (p=0.029, p=0.016, and p=0.028, respectively) in the study patients with chronic hepatitis C treated with the combination therapy of PEGIFN α and RBV.
|
26614853 |
2015 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
Recent studies in chronic hepatitis C patients have shown that rs368234815 polymorphism nearby IL28B is a better predictor of response to antiviral treatment with pegylated interferon and ribavirin than IL28B polymorphisms (rs12979860 and rs8099917).
|
25130512 |
2014 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
Patients with genotype 1b chronic hepatitis C (n = 446) treated with peg-interferon alpha and ribavirin (RBV) for 48 weeks were genotyped for the ITPA (rs1127354) and IL28B (rs8099917) genes.
|
23297176 |
2013 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.
|
21879313 |
2012 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) in IL28B and serum levels of interferon γ inducible protein 10 (IP-10) predict outcomes of antiviral therapy in patients with chronic hepatitis C. We associated IL28B SNPs rs12979860 and rs8099917, along with serum levels of IP-10, with outcomes of patients with acute hepatitis C (AHC).
|
22192885 |
2012 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASCAT |
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.
|
21228123 |
2011 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASDB |
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.
|
21228123 |
2011 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
We genotyped chronic hepatitis C (CHC) genotype 1 patients with PegIFN/R treatment-induced clearance (n = 417) and treatment failure (n = 493), and 234 individuals with spontaneous clearance, for HLA-C C1 versus C2, presence of inhibitory and activating KIR genes, and two IL28B SNPs, rs8099917 and rs12979860.
|
21931540 |
2011 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
These results demonstrate that the genotypes rs12979860 CC and rs8099917 TT were more frequently observed in Korean patients compared to other ethnicities, and suggest that the genetic characteristics of patients may be prognostic factor that predicts antiviral response to PEG-IFN therapy for chronic hepatitis C.
|
21907615 |
2011 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
The rs8099917 polymorphism should be the best predictor for the response to the PEG-IFN/RBV treatment among Japanese chronic hepatitis C patients.
|
21389156 |
2011 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
BEFREE |
With the screening for IL28B polymorphisms rs12980275, rs8099917 and rs12979860, which are associated with HCV chronicity and with reduced SVR rates, an important prognostic factor of the therapy of chronic hepatitis C can be easily diagnosed.
|
21149916 |
2010 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASCAT |
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
|
20060832 |
2010 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASDB |
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
|
20060832 |
2010 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASDB |
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
|
19749757 |
2009 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASCAT |
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
|
19749758 |
2009 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASCAT |
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
|
19749757 |
2009 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASDB |
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
|
19749758 |
2009 |
|
Hepatitis C, Chronic
|
|
0.900 |
GeneticVariation
|
GWASDB |
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
|
19684573 |
2009 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sensitivity analyses suggested the robustness of the results in this meta-analysis.Both IL28B rs12979860 CC and rs8099917 TT genotypes are protective factors for the development of HCC among patients with HBV or HCV infection.
|
31568008 |
2019 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results of treatment response showed that CC (major) genotype of IFNL3 (rs12979860) and TT (major) genotype of IFNL3 (rs8099917) are associated with the likelihood of achieving a higher sustained virological response (SVR), to combined daclatasvir and sofosbuvir therapy, in genotype 3-infected HCV patients, whereas the individuals with TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) are more susceptible to chronic HCV infection and treatment relapse, suggesting a role of IFNL3 (rs12979860) and (rs8099917) in the treatment outcome of combined daclatasvir and sofosbuvir therapy in chronic HCV genotype 3 infection.
|
30431653 |
2019 |
|
Pseudohyperkalemia Cardiff
|
|
0.100 |
GeneticVariation
|
BEFREE |
Similarly, GG-GG (PNPLA3-IL28B) is considered a high-risk signature for higher degree of fibrosis.<b>Conclusion:</b> IL28B rs8099917 and PNPLA3 rs738409 introduce genetic signature to identify patients at higher risk for CHC susceptibility and fibrosis progression in CHC G4.
|
31793339 |
2019 |